Two primary strategies include GDF15 analogues as GFRAL agonists for obesity treatment and GDF15‐derived peptides as antagonists to counteract cancer‐induced cachexia and related disorders. Here, GFRAL is linked to obesity due to melanocortin 4 receptor deficiency.